EUVIMEDObjevte EUVIMED
Kohortenstudie

Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study

Xin Shen, Fan Wang, Rui Wang, Huan Liu, Erle Dang iD, Chen Yu iD, Gang Wang iD

Experimental Dermatology · 2026-04 · 35 (4)

DOI: 10.1111/exd.70252 ↗

At a glance

Kohortenstudie in Experimental Dermatology, published online on 2026-04-13. Written by Xin Shen and 6 co-authors. Institution: Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Major MEDLINE topics: Psoriasis, Body Mass Index, Biological Products. Cited 2 times so far (Crossref); 33 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Obesity reduces response to biologic therapy in psoriasis, but comparative evidence across drug classes in Chinese patients is limited. A real‐world cohort of 891 adults with moderate‐to‐severe psoriasis initiating biologics between 2020 and 2025 was divided by baseline BMI (< 24 vs. ≥ 24 kg/m 2 ). PASI90 achievement at 2, 4, 6 and 12 months and drug survival were compared amongst IL‐17, IL‐23 and TNF‐α inhibitors. Amongst IL‐17 users, PASI90 rates in the non‐overweight group were consistently higher at 4, 6 and 12 months (all p < 0.05), whereas no BMI‐related differences were seen with TNF‐α or IL‐23 blockade. Within the non‐overweight stratum, IL‐17 and IL‐23 agents outperformed TNF‐α inhibitors at month 6 and yielded fewer switches ( p < 0.05). In the overweight/obese stratum, IL‐23 blockade achieved the highest PASI90 rates and longest drug survival versus both IL‐17 and TNF‐α inhibitors ( p < 0.05). In this real‐world cohort of Chinese psoriasis patients, BMI was observed to correlate with biologic effectiveness in a drug‐specific manner. Our findings suggest that whilst IL‐17 or IL‐23 inhibitors showed favourable outcomes for non‐overweight individuals, IL‐23 blockade may be associated with a more sustained response in those categorised as overweight or obese.

Subjects

MeSH terms (MEDLINE)

PsoriasisBody Mass IndexBiological ProductsHumansFemaleMaleTumor Necrosis Factor-alphaAdultInterleukin-17Middle AgedObesityInterleukin-23Severity of Illness IndexCohort StudiesTreatment OutcomeAntibodies, Monoclonal, Humanized

Author keywords

biologic agentsbody‐mass indexlong‐term efficacypsoriasisreal‐world study

Substances

Tumor Necrosis Factor-alphaInterleukin-17Interleukin-23Biological ProductsAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.

ORCID profiles: Erle Dang, Chen Yu, Gang Wang

Cite

APA

Shen, X., Wang, F., Wang, R., Liu, H., Dang, E., Yu, C., & Wang, G. (2026). Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study. Experimental Dermatology, 35(4). https://doi.org/10.1111/exd.70252

Vancouver

Shen X, Wang F, Wang R, Liu H, Dang E, Yu C, et al. Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study. Experimental Dermatology. 2026;35(4). doi:10.1111/exd.70252

BibTeX
@article{Shen2026,
  author = {Shen, Xin and Wang, Fan and Wang, Rui and Liu, Huan and Dang, Erle and Yu, Chen and Wang, Gang},
  title = {Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study},
  journal = {Experimental Dermatology},
  year = {2026},
  volume = {35},
  number = {4},
  doi = {10.1111/exd.70252}
}
Start for free →